Octaplaslg (Human Plasma Protein)

Human plasma protein fraction, the active ingredient in OctaplasLG, is a plasma protein fraction presented as a lyophilized powder for reconstitution for intravenous use. It supports hemostasis and replaces deficient clotting factors in patients with bleeding disorders, liver disease‑related coagulopathy, or requiring massive transfusion.

GNH USA supplies OctaplasLG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

OctaplasLG, a plasma protein fraction, is used to manage disorders of coagulation and bleeding. - Replacement therapy for clotting factor deficiencies: Provides necessary clotting factors to patients with inherited or acquired deficiencies, helping to achieve hemostasis. - Management of bleeding in patients with liver disease: Supplies coagulation proteins that are often reduced in hepatic impairment, reducing bleeding risk. - Massive transfusion support: Supplements plasma proteins and clotting factors during large‑volume transfusions, aiding in maintaining hemostatic balance.

OctaplasLG may be associated with infusion‑related reactions and rare immunologic events.

Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Chills: mild to moderate shaking sensations. - Nausea: occasional feeling of queasiness. - Headache: mild headache reported post‑infusion.

Serious or Rare Side Effects: - Allergic reaction: anaphylaxis or severe hypersensitivity requiring immediate medical attention. - Transfusion‑related acute lung injury (TRALI): acute respiratory distress following infusion. - Volume overload: signs of fluid overload such as pulmonary edema. - Hemolysis: rare destruction of red blood cells.

When using OctaplasLG, clinicians should observe several safety considerations. - Patient screening: assess for known plasma protein allergies or prior transfusion reactions. - Infection risk: verify donor screening and product viral inactivation status. - Coagulopathy monitoring: regularly check coagulation parameters during therapy. - Volume status: monitor for signs of fluid overload, especially in cardiac patients. - Concomitant anticoagulants: adjust dosing of anticoagulant drugs as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

OctaplasLG can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): may blunt the hemostatic effect and increase bleeding risk. - Antiplatelet drugs (e.g., aspirin, clopidogrel): combined use can exacerbate bleeding tendencies.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may alter immune response to plasma proteins. - High‑dose steroids: could affect plasma protein metabolism. - Other blood products (e.g., red cell concentrates): monitor for cumulative volume and coagulation changes.